IPL vs LLLT: How They Differ and Why They Combine
Intense pulsed light and low-level light therapy are both light-based, but they are not interchangeable, and the value of Espansione's platform lies precisely in their differences. Understanding how they diverge explains why LM™ LLLT (PBM) is the primary modality and OPE™ IPL the adjunct, and why combining them addresses more of a patient's disease than either alone.
The core difference
LM™ LLLT (PBM) is photobiomodulation: a single, non-thermal, monochromatic wavelength that acts on cellular activity, promoting mitochondrial ATP release, modulating inflammation and supporting tissue recovery. Its reach is broad, spanning the tear film, the eyelids and the ocular surface.
OPE™ IPL is polychromatic light delivered in calibrated thermal pulses. Its effect is concentrated at the eyelid and its margin, where it warms and supports gland function and addresses the inflammatory and vascular component of meibomian gland dysfunction.
| LM™ LLLT (PBM) | OPE™ IPL | |
|---|---|---|
| Light type | Monochromatic, non-thermal | Polychromatic, calibrated thermal pulses |
| Primary action | Cellular, on mitochondria and inflammation | Glandular and vascular, at the lid |
| Tissue reach | Tear film, eyelids, ocular surface | Eyelid and lid margin |
| Role | Primary modality | Adjunct for severe or recalcitrant MGD |
| Gel required | No | No (gel-free design) |
| Key safety note | Favourable profile, no absolute contraindications identified | Screen for photosensitivity and photosensitising medication |
Why combine them
Most dry eye patients carry several drivers at once. LLLT drives cellular recovery and reaches the aqueous layer and ocular surface that IPL does not, while IPL works on the inflammatory and glandular drivers at the lid. Treating the lid with one and the broader surface with the other addresses more of the driver profile in a single plan, which is the logic behind combined therapy.
What the head-to-head evidence shows
In a direct comparison, LM™ LLLT improved symptoms and tear meniscus height more than OPE™ IPL at two weeks (Giannaccare et al., 2022, Cornea), supporting LLLT's role as the primary modality. Combination therapy then outperformed IPL-only approaches at eighteen months (Leite et al., 2025) and bettered competitor IPL-only devices on lipid layer thickness and symptoms (Castro et al., 2023). The honest reading is that LLLT leads, and IPL adds value as an adjunct for lid-driven, inflammatory cases, rather than that either is universally superior.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.